IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals
Due to the growing interest of International Atomic Energy Agency (IAEA) Member States in implementing targeted radionuclide therapy (TRT) in general, the demand for alpha-emitting radionuclides and radiopharmaceuticals is enormous. As an international platform for peaceful applications of radionuclides, the IAEA has been implementing several activities focusing on the production and quality control of alpha emitters and radiopharmaceuticals as well as capacity building in the field, through Technical Meetings, Workshops, Publications and Conference Supports, IAEA-Coordinated Research Projects (CRP) and Technical Cooperation Program (TC). This review article summarises the IAEA activities on the production and quality control of alpha emitter radiopharmaceuticals for targeted alpha therapy (TAT) and a roadmap to future steps including but not limited to the ongoing CRP on 225Ac-radiopharmaceuticals
JALILIAN Amirezza;
KLEYNHANS Janke;
BOUZIOTIS Penelope;
BRUCHERTSEIFER Frank;
CHAKRABORTY S.;
DE BLOIS Erik;
DENECKE Melissa;
ELBOGA U;
GIZAWY M;
HORAK C;
JANG J;
KORDE Aruna;
MAJKOWSKA PILIP Agnieszka;
MDLOPHANE Amanda;
OCAMPO-GARCIA B;
SELIVANOVA S.V.;
STAROVOITOVA Valeriia;
WOJDOWSKA W;
ZEEVART Jan;
RADCHENKO Valery;
2025-11-28
ELSEVIER SCIENCE INC
JRC144851
1872-9614 (online),
https://doi.org/10.1016/j.nucmedbio.2025.109008,
https://publications.jrc.ec.europa.eu/repository/handle/JRC144851,
10.1016/j.nucmedbio.2025.109008 (online),
Additional supporting files
| File name | Description | File type | |
|---|
